415 related articles for article (PubMed ID: 2856115)
21. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
22. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
23. Real-time monitoring of phosphodiesterase inhibition in intact cells.
Herget S; Lohse MJ; Nikolaev VO
Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
[TBL] [Abstract][Full Text] [Related]
24. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
[TBL] [Abstract][Full Text] [Related]
25. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
26. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
27. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
Thomas RE; Armstrong DT; Gilchrist RB
Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
[TBL] [Abstract][Full Text] [Related]
29. High activity of low-Michaelis-Menten constant 3', 5'-cyclic adenosine monophosphate-phosphodiesterase isozymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus.
Takeda S; Lin CT; Morgano PG; McIntyre SJ; Dousa TP
Endocrinology; 1991 Jul; 129(1):287-94. PubMed ID: 1647298
[TBL] [Abstract][Full Text] [Related]
30. Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activities in rabbit ventricular myocardium: relations to post-natal maturation.
Kithas PA; Artman M; Thompson WJ; Strada SJ
J Mol Cell Cardiol; 1989 May; 21(5):507-17. PubMed ID: 2550653
[TBL] [Abstract][Full Text] [Related]
31. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
Verghese MW; McConnell RT; Lenhard JM; Hamacher L; Jin SL
Mol Pharmacol; 1995 Jun; 47(6):1164-71. PubMed ID: 7603456
[TBL] [Abstract][Full Text] [Related]
32. Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects.
Silver PJ; Allen P; Etzler JH; Hamel LT; Bentley RG; Pagani ED
Second Messengers Phosphoproteins; 1990; 13(1):13-25. PubMed ID: 2286932
[TBL] [Abstract][Full Text] [Related]
33. Insulin activation of cyclic AMP phosphodiesterase in intact ureteral segments.
Weiss RM; Wheeler MA
J Pharmacol Exp Ther; 1988 Nov; 247(2):630-4. PubMed ID: 2846825
[TBL] [Abstract][Full Text] [Related]
34. Characterization of human placental cytosolic adenosine 3',5'-monophosphate phosphodiesterase by inhibitors and insulin treatment.
Xiong LM; LeBon TR; Fujita-Yamaguchi Y
Endocrinology; 1990 Apr; 126(4):2102-9. PubMed ID: 2156681
[TBL] [Abstract][Full Text] [Related]
35. Central effects of the preservative, methylparaben. In vivo activation of cAMP-specific phosphodiesterase and reduction of cortical cAMP.
Harvey BH; Carstens ME; Taljaard JJ
Biochem Pharmacol; 1992 Sep; 44(6):1053-7. PubMed ID: 1329756
[TBL] [Abstract][Full Text] [Related]
36. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
38. [Effect of several hormones on cyclic 3',5'-nucleotide phosphodiesterase in rat kidneys].
Iwase K
Nihon Naibunpi Gakkai Zasshi; 1983 Oct; 59(10):1678-91. PubMed ID: 6319206
[TBL] [Abstract][Full Text] [Related]
39. Localization of low-KM cAMP phosphodiesterase in rat nephron segments.
Yoshida I; Takeda S; Homma S; Kusano E; Asano Y
Kidney Blood Press Res; 1997; 20(5):307-11. PubMed ID: 9419046
[TBL] [Abstract][Full Text] [Related]
40. Positively cooperative cAMP phosphodiesterase attenuates cellular cAMP responses.
Barber R; Goka TJ; Butcher RW
Second Messengers Phosphoproteins; 1992; 14(1-2):77-97. PubMed ID: 1383507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
